One-Week radiation for breast cancer: MRI precision may cut side effects

NCT ID NCT03936478

Recruiting now Disease control Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new radiation approach for early breast cancer that uses real-time MRI guidance to deliver just three high-dose sessions over one week, instead of the usual several weeks. The goal is to see if this shorter treatment is safe, preserves the breast's appearance, and limits damage to healthy tissue. The trial enrolls people who have had a lumpectomy for early-stage breast cancer or certain precancers, and follows them for up to five years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MRI-guided partial breast irradiation (3 fractions of 8.2 Gy)
What this could lead to: If successful, this could offer a shorter, more precise radiation option for early breast cancer, potentially reducing side effects and improving cosmetic outcomes.
What could go wrong: This is a small phase 2 study with only 30 participants, so results may not apply to all patients. The long-term safety and effectiveness beyond 5 years are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm ductal breast carcinoma in situ invasive breast carcinoma lobular breast carcinoma in situ

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER DCIS LCIS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

University of Wisconsin Carbone Cancer Center
RECRUITING

Madison, Wisconsin, 53705, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.